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Abstract
 
Binding of the T cell receptor (TCR) to a bacterial superantigen (SAG) results in stimulation of
a large population of T cells and subsequent inflammatory reactions. To define the functional
contribution of TCR residues to SAG recognition, binding by 24 single-site alanine substitu-
 
tions in the TCR V
 
b
 
 domain to 
 
Staphylococcus aureus 
 
enterotoxin (SE) C3 was measured, pro-
ducing an energy map of the TCR–SAG interaction. The results showed that complementarity
determining region 2 (CDR2) of the V
 
b
 
 contributed the majority of binding energy, whereas
hypervariable region 4 (HV4) and framework region 3 (FR3) contributed a minimal amount of
energy. The crystal structure of the V
 
b
 
8.2–SEC3 complex suggests that the CDR2 mutations
act by disrupting V
 
b
 
 main chain interactions with SEC3, perhaps by affecting the conforma-
tion of CDR2. The finding that single V
 
b
 
 side chain substitutions had significant effects on
binding and that other SEC3-reactive V
 
b
 
 are diverse at these same positions indicates that
SEC3 binds to other TCRs through compensatory mechanisms. Thus, there appears to be
strong selective pressure on SAGs to maintain binding to diverse T cells.
Key words: T cell receptor • superantigens • 
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Introduction
 
A T cell recognizes ligand through the interaction of its 
 
a
 
/
 
b
 
TCR and an antigenic peptide expressed in the context of
an MHC (pMHC). This process of MHC restriction pro-
vides for the specificity of T cell responses to pathogens. Su-
 
perantigens (SAGs)
 
1
 
 are proteins of viral or bacterial origin
that stimulate T cell populations by binding and cross-link-
ing the TCR with a class II MHC product, thus circum-
venting the normal recognition of intracellularly processed
pMHC (1). Because SAGs can bind to V
 
b
 
 regions directly,
SAG engagement of T cells leads to polyclonal expansion of
up to 20% of all T cells. In contrast, normal pMHC antigen
recognition might involve the stimulation of as few as only 1
in 10
 
5
 
 or 10
 
6
 
 T cells (2). SAG-mediated recognition can lead
to hyperactive responses associated with the release of T cell
cytokines or to T cell deletion and anergy (3, 4). It has also
been suggested that SAG-mediated effects may contribute to
particular autoimmune and inflammatory disorders (3).
 
Two classes of SAGs have been identified: endogenous ret-
roviral-encoded cellular-bound proteins, such as mouse mam-
mary tumor virus (MMTV)-encoded Mls antigen, and exoge-
nous soluble proteins secreted from bacteria (4–6). The latter
 
SAGs include 
 
Mycoplasma arthritidis
 
 mitogen (7, 8), streptococ-
cal pyrogenic exotoxins (9–11), staphylococcal toxic shock
syndrome toxin 1, enterotoxins, and exfoliative toxins (1, 9).
Most structural and biological activity studies have focused on
the SAGs of 
 
Staphylococcus aureus
 
,
 
 
 
which have been associated
with food poisoning and toxic shock syndrome (3).
 
The 
 
S
 
.
 
 aureus 
 
enterotoxins (SEs) exist in isoforms A–E and
G–I (12), which bind to numerous V
 
b
 
 families of murine
and human origin (1). The structures of SEs to date reveal a
conserved architecture, consisting of a small NH
 
2
 
-terminal
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Abbreviations used in this paper:
 
 
 
DD
 
G, change in free energy; FR,
framework region; HRP, horseradish peroxidase; HV, hypervariable re-
gion; IC
 
50
 
, half-maximal inhibitory concentration; 
 
K
 
D
 
, equilibrium bind-
ing constant; pMHC, peptide-MHC complex; SAG, superantigen; sc,
single-chain; SE, 
 
Staphylococcus aureus
 
 enterotoxin; SPR, surface plasmon
resonance; vdw, Van der Waals; wt, wild-type. 
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Superantigen–TCR Interactions
 
b
 
-barrel domain and a large COOH-terminal domain that
contains a 
 
b
 
-grasp motif, connected by a long solvent-acces-
sible 
 
a
 
 helix (2). Early studies suggested that the SE-binding
site of the TCR was positioned away from the conventional
pMHC combining site (13). The V
 
b
 
 cross-reactivity pos-
sessed by SEs suggested that the proteins bound to conserved
structural elements of the TCR shared among different V
 
b
 
regions (1). Mutagenesis studies indicated that CDR2, and
perhaps CDR1 to a lesser degree, were involved in the reac-
tivity with SEB and SEA (14).
The recent crystallographic structures of SEC3 and SEB in
complex with the V
 
b
 
8.2 region of the mouse TCR 14.3.d
(15, 16) revealed that CDR2, hypervariable region 4 (HV4),
and framework region 3 (FR3) contact these SAGs. In both
complexes, CDR2 occupied the cleft between the large and
small domains of SEC3 and shared multiple contacts and hy-
drogen bonds with each domain (17). CDR2 contained the
majority of surface contacts for SEC3 (63%) and for SEB
(50%), and these contacts involved exclusively V
 
b
 
 main
chain atoms. The FR3 region of the V
 
b
 
 domain contributed
32 and 34% of the contacts with SEC3 and SEB, whereas
HV4 provided 7 and 9% of the contacts with SEC3 and SEB
(16). Direct contacts with CDR1 and CDR3 were not ob-
served in either complex. Therefore, SE binding to the
TCR incorporates regions of the TCR that are essential in
pMHC binding (CDR2), while also involving regions that
are not important in pMHC recognition (FR3 and HV4).
SAGs stimulate T cells not just by binding to the TCR,
but by binding a class II MHC product through a different
face of the SAG molecule. This TCR–SAG–pMHC ternary
complex brings a T cell together with a class II
 
1
 
 cell and it
presumably leads to TCR clustering at the T cell surface.
The stoichiometry of these interactions has yet to be fully
determined and may vary among the different SAGs (12).
Nevertheless, recent evidence showed that the V
 
a
 
 of the
TCR appears to be involved in binding to the class II MHC
product and thereby increasing the stability of the complexes
(18). This finding is consistent with the initial work of
Blackman and colleagues and more recently from other
groups that suggested that SAG-mediated effects may in-
volve CDR3 of the 
 
b
 
 chain and the V
 
a
 
 region (8, 19–25).
The latter conclusions were based on evidence of restrictions
in either CDR3 residues or V
 
a
 
 regions that were expressed
by a specific V
 
b
 
1
 
 population that reacted with an SAG.
Although the structure of individual components and the
complexes have provided a view of the contact residues,
mutagenesis studies can provide a quantitative view of the
residues that are of importance from the energetic perspec-
tive. These interactions usually represent a subset of the in-
terface residues identified as contacts in the crystal structure
(26). However, even the same protein surface can involve
either only a few very important residues in ligand binding
(e.g., the antibody D1.3 in its interaction with hen egg
lysozyme) or a larger number of moderately important resi-
dues (e.g., the D1.3 interaction with its antiidiotype anti-
body E5.2) (27). This possibility is important with regard to
V
 
b
 
–SEC3 interactions, as it is possible that the majority of
the energy could be derived from only a few contacts and
 
these contacts might be conserved among the different
SEC3-reactive V
 
b
 
 regions.
To define the functional contribution of individual
TCR residues toward SEC3 recognition, we have used ala-
nine scanning mutagenesis of a V
 
b
 
8.2 TCR from the T
cell clone 2C. Due to the relatively low affinity of the
SEC3–V
 
b
 
8.2 TCR interaction (equilibrium binding con-
stant [
 
K
 
D
 
] 
 
. 
 
10 
 
m
 
M), an affinity-matured SEC3 variant
(
 
K
 
D
 
 
 
z
 
 180 nM) was used to facilitate the mutagenic bind-
ing studies. Residues in CDR1 and CDR2, and to a lesser
degree HV4 and FR3, served as energetic hotspots for
binding to the SEC3 variant. Based on the structure of the
V
 
b
 
8–SEC3 complex (16), most of the CDR1 energy was
predicted to be involved in binding the region of the SEC3
variant that had been mutated to yield higher affinity.
Thus, CDR2 contributed the majority of the energy to the
interaction of V
 
b
 
8.2 and the wild-type (wt) SEC3. HV4
and FR3 contributed less energy than would be predicted
from their contribution to the total contact area of the
complex. The observation that CDR2 mutations affected
binding to SEC3 is somewhat surprising in the sense that all
of the contacts found at the CDR2–SEC3 interface in-
volved V
 
b
 
 main chain interactions (16). Side chain substi-
tutions could be affecting these main chain interactions
through conformational changes in the V
 
b
 
8 backbone.
As other V
 
b
 
 regions that interact with SEC3 exhibit even
more amino acid variability at the energetically important
positions (i.e., than a single alanine mutation), there appears
to be extensive diversity at the molecular level in the binding
of SEC3 to different V
 
b
 
 regions. Thus, from a consideration
of binding energies the results provide evidence that the
same SAG may require compensatory interactions among
different V
 
b
 
 regions. These interactions could involve other
residues within the V
 
b
 
 (i.e., residues different from those im-
portant in the V
 
b
 
8.2–SEC3 interaction) or residues within
CDR3 loops or V
 
a
 
 regions that act by contacting and sta-
bilizing the interaction with class II MHC. In light of the
minimal binding energy differences that are known to elicit
agonist versus antagonist responses (28, 29), the results also
suggest how the same SAG could yield widely disparate bio-
logical affects, depending on the V
 
b
 
 region involved.
 
Materials and Methods
 
TCR Mutagenesis.
 
Alanine-substituted single-chain (sc)TCRs
were constructed as thioredoxin fusion proteins with a His
 
6 
 
tag
using two mutagenesis methods. First, a PCR-based technique
(30) used a short mutagenic primer and a V
 
b
 
-specific primer to
generate a “megaprimer,” which was isolated and used in a sec-
ond PCR with the opposing V
 
a
 
-specific primer. All PCRs were
carried out using cloned 
 
Pfu 
 
DNA polymerase (Stratagene). The
KpnI/BamHI-digested PCR product was ligated into a pUC-
19M vector, transformed into 
 
Escherichia coli
 
 strain DH5-
 
a
 
 for
sequencing. The scTCR inserts were then subcloned into the
pTRXFus vector (Invitrogen) and transformed into 
 
E
 
.
 
 coli 
 
strain
GI698 for expression. Alternatively, “QuikChange” site-directed
mutagenesis (Stratagene) was used to mutagenize the wt-scTCR-
pTRXFus. The DpnI-digested product was transformed into 
 
E
 
.
 
coli 
 
strain GI698 for sequencing and expression. 
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TCR Expression and Purification.
 
Proteins were expressed in
 
E
 
.
 
 coli
 
 strain GI698 as described previously (31) and purified
from inclusion bodies by denaturing affinity chromatography us-
ing His-Bind resin (Novagen). After renaturation by dialysis
(31), the monomeric proteins were purified by Superdex 200 gel
filtration (Amersham Pharmacia Biotech) using HPLC.
 
mAbs.
 
KJ16 (32) is a rat IgG mAb specific for mouse V
 
b
 
8.1
and V
 
b
 
8.2 regions of the TCR. F23.1 (33) is a mouse IgG2a mAb
specific for mouse V
 
b
 
8.1, V
 
b
 
8.2, and V
 
b
 
8.3 regions. F23.2 (33) is
a mouse IgG1 mAb specific for the mouse V
 
b
 
8.2 region. Antibod-
ies were purified from either culture supernatants or ascites, fol-
lowed by protein G– and protein A–agarose (GIBCO BRL) col-
umn chromatography for KJ16 and F23.1/F23.2, respectively.
 
SEC3 Purification.
 
SEC3 variant 1A4 (SEC3-1A4) was iso-
lated from a phage display library (Anderson, P.S., and R.A.
Mariuzza, manuscript in preparation). Soluble protein was pre-
pared as described previously (18). In brief, bacterial expression
was induced at mid-log density by the addition of isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG) and continued for 4 h. The
protein was purified from the periplasmic fraction using a RedA
dye–agarose matrix (Amicon), followed by chromatography us-
ing a monoQ column (Amersham Pharmacia Biotech).
 
ELISAs.
 
V
 
b
 
8
 
-
 
specific competition ELISAs were performed
by adsorption of KJ16, F23.1, or F23.2 to the wells of Immulon
2HB analytical plates (Dynatech Labs). The wells were blocked
with PBS that contained 0.25% BSA and 0.05% Tween 20. After
washing, 100 
 
m
 
l of mutant or wt-scTCR and 50 
 
m
 
l of biotiny-
lated wt-scTCR were added to the wells for 1 h The wells were
then washed, and binding was detected using horseradish perox-
idase (HRP)-streptavidin followed by tetramethylbenzidine (TMB)
peroxidase substrate (Kirkegaard & Perry). The relative half-
maximal inhibitory concentration (IC
 
50
 
) for each mutant relative
to wt was calculated using linear regression analysis.
SEC3-1A4 competition ELISAs were performed by adsorption
of wt-scTCR to the wells of the analytical plates. The wells were
blocked and after washing, 50 
 
m
 
l of mutant or wt-scTCR and 50
 
m
 
l of biotinylated SEC3-1A4 were added to the wells. After 1 h,
the wells were washed and binding was detected using HRP-
streptavidin followed by TMB substrate. The relative IC
 
50
 
 for each
mutant relative to wt was calculated using linear regression analysis.
SEC3-1A4 reactivity was normalized for V
 
b
 
8 reactivity to account
for variations in the percentages of properly folded scTCRs.
BIAcore Analysis. Surface plasmon resonance (SPR) studies
were performed using a BIAcore 1000® instrument. Binding ex-
periments were as described previously (17, 18). SEC3-1A4 was
immobilized on the sensor chip, and various concentrations of
scTCR were allowed to bind until equilibrium was reached (1–5
min). The response, corrected for nonspecific binding and ag-
gregation (34), was used to determine the equilibrium binding
constant (KD) by Scatchard analysis.
Structural Analysis. Structural analysis was performed on an
O2 work station (Silicon Graphics) using Quanta 97 Software
(Molecular Simulations). The structure of 14.3.d b chain–SEC3
complex (15), in conjunction with the structure of 2C TCR
(35), was used to assign SEC3 contacts for those 2C residues
tested by mutagenesis.
Results
Binding of 2C scTCR to SEC3 Wt and SEC3 Variant
1A4.  The TCR used here is derived from the murine
CTL clone 2C (36), which recognizes the allogeneic MHC
Ld (37) and the syngeneic MHC Kb (38). The 2C TCR
contains the Va3.1 region and the Vb8.2 region. With the
exception of CDR3b, this is the same Vb expressed by the
TCR 14.3.d that was crystallized as a complex with SEC3
(15). The 2C TCR was produced as a single chain contain-
ing an NH2-terminal thioredoxin domain (for increased sol-
ubility), the Vb region, a 24-residue linker, and the Va re-
gion (31). The reactivity of the scTCR construct is similar
to the native receptor for the allogeneic MHC ligand Ld (39,
40) and its syngeneic MHC ligand Kb (Lee, P.U.Y., H.R.O.
Churchill, and D.M. Krantz, unpublished results).
The mAbs KJ16, F23.1, and F23.2 (32, 33) recognize
conformational epitopes on the Vb8 region (41). KJ16 and
F23.1 react with framework regions (FRs) of the Vb8 do-
main while F23.2 reacts with CDR1 and CDR2 residues
(42). To develop a sensitive, quantitative binding assay for
TCR mutants, we made use of an SEC3 variant, 1A4, that
has a higher affinity for the TCR. This SEC3 variant was
isolated by phage display of a library of SEC3 mutants, fol-
lowed by selection on immobilized 14.3.d b chain (18). The
SEC3 library contained random variants at five residues
(102Gly, 103Lys, 104Val, 105Thr, and 106Gly) of the disul-
fide loop within the small domain of SEC3. Variant 1A4 and
wt SEC3 were examined for binding to the 2C scTCR in a
competition assay and in BIAcore analyses. The competition
assay involved immobilization of F23.2 or KJ16 on wells,
followed by addition of biotinylated scTCR and streptavi-
din-HRP. SEC3 wt and 1A4 were titrated as unlabeled
inhibitors of this reaction (Fig. 1), showing that 1A4 was an
z290-fold better inhibitor. Results were similar with either
F23.2 or KJ16 as the immobilized antibody (data not shown).
SPR (BIAcore) analyses were performed using titrations
of the 2C scTCR with either wt SEC3 or 1A4 immobi-
lized on the surface of a chip (see below and Fig. 6). Based
on equilibrium binding titrations, the wt 2C scTCR dis-
Figure 1. Relative TCR reactivities of SEC3 and SEC3 variant 1A4.
Various concentrations of SEC3 wt and SEC3 variant 1A4 were used to
inhibit binding of biotinylated scTCR to immobilized mAb KJ16 in an
ELISA format. Bound biotinylated scTCR was detected by streptavidin-
HRP. The relative reactivity of each SAG was determined as the ratio of
SAG to scTCR IC50 by linear regression analysis. Similar results were ob-
tained with immobilized mAb F23.2 (data not shown).838 Superantigen–TCR Interactions
played a KD of 180 6 55 nM for the SEC3-1A4 variant,
but the affinity for the wt SEC3 was not measurable (KD .
5 mM) at the concentrations of scTCR that could be tested
(i.e., the solubility limit of the 2C scTCR). Thus, the affin-
ity of SEC3-1A4 was at least 30-fold higher based on this
assay method. Similar results were obtained for binding of
wt SEC3 and SEC3-1A4 variant to immobilized 14.3.d
TCR-a/b yielding KD values of 22 mM and 150 nM, re-
spectively (data not shown). Together, these results showed
that the SEC3-1A4 variant had sufficient affinity to per-
form a mutagenic analysis.
Characterization of 2C TCR Mutants. To analyze the
interface between the TCR and SEC3-1A4, 29 single-site
alanine mutants of the 2C scTCR (Fig. 2) were expressed
in E. coli and purified by Ni column chromatography and
gel filtration. As Vb residue 52 is alanine, this position was
mutated to tryptophan. The reactivities of the KJ16 and
F23.1 antibodies with the mutant scTCR provided a mea-
sure of the concentration of folded protein in the prepara-
tions of refolded scTCR. Monomeric scTCR mutants
were evaluated for Vb-specific mAb reactivity in a compe-
tition ELISA using biotinylated wt-scTCR. The degree of
properly folded scTCRs was determined from inhibition
curves, as the IC50 relative to wt-scTCR (Fig. 3). The av-
erage reactivity of KJ16 and F23.1 with the scTCR was
used as a measure of the concentration of properly folded
protein.
23 of the single-site mutants showed reactivity with the
anti-Vb antibodies, KJ16 and F23.1, indicating that they
were properly folded. Seven mutants (Vb residues 25bGln,
29bHis, 32bMet, 49bSer, 54bSer, 69bArg, and 75bPhe)
had minimal or no mAb reactivity. Most of these are inac-
cessible residues in which the side chains are likely to be in-
volved in the stability of the CDR or HV4 loops (35). Mu-
tations in the three CDRs and HV4 could be evaluated
using KJ16 and F23.1, as these loops are not part of the
KJ16 or F23.1 epitopes. Because mutations in the FRs
57bLys and 66bLys might affect binding to KJ16 and/or
F23.1, mAb F23.2 was also used as verification of proper
refolding of these mutants. The Lys57bAla and Lys66bAla
mutants bound to F23.2, KJ16, and F23.1 with reactivities
similar to the wt-scTCR, indicating that these residues do
not contribute energy to the epitopes of any of these Vb8-
specific mAbs and that the mutants were properly refolded.
Binding of Single-Site TCR Mutants to SEC3-1A4.
Binding affinities of the TCR mutants were also examined
in two different assays. In one assay, an ELISA was per-
formed with immobilized wt-scTCR followed by the ad-
dition of biotinylated SEC3-1A4 and streptavidin-HRP.
The measurement of mutant scTCR affinities was evalu-
ated by titrations with unlabeled scTCR to compete for
SEC3 binding to the immobilized wt-scTCR. From the
generation of binding inhibition curves (Fig. 4), the SEC3-
1A4 reactivity was determined as the IC50 ratio of mutant
Figure 2. 2C scTCR alanine substitutions and protein expression. Alanine mutants that can be expressed and properly refolded are indicated. Proteins
listed as having an expression defect possessed minimal or no Vb8-specific mAb activity by ELISA (see Fig. 3).
Figure 3. Reactivity of scTCR alanine mutants with anti-Vb8 anti-
bodies. The relative reactivity of the mutant scTCR proteins toward the
Vb8-specific antibodies KJ16 (A) and F23.1 (B) were evaluated in a com-
petition ELISA format. Various concentrations of wt and mutant scTCRs
were used to inhibit the binding of biotinylated wt-scTCR to each anti-
body, followed by detection with streptavidin-HRP. The IC50 ratio of
mutant to wt by linear regression analysis was used as a measure of anti-
body reactivity. The average value for each mutant was used as a normal-
ization factor for properly refolded protein.839 Churchill et al.
to wt-scTCR. The average value of three or more inde-
pendent assays was used to determine binding affinities, rel-
ative to wt-scTCR (Fig. 5). In the other assay, BIAcore
analyses were performed with immobilized SEC3-1A4.
Various concentrations of mutant scTCRs were allowed to
reach binding equilibrium, and the KD of each mutant rela-
tive to wt-scTCR was determined by Scatchard analysis
(43; Fig. 6). The values determined by the competition
ELISA and SPR were completely consistent (Table I).
Only the reactivity values determined from the competi-
tion assay are summarized as the bar graph in Fig. 5.
Many alanine scanning studies have shown that only a
few mutations at a subset of the contact residues result in
large (.10-fold) reductions in binding. In the TCR scan,
only 6 of the 25 TCR residues tested affected the binding
of SEC3-1A4 by .10-fold (Fig. 5). These six residues were
distributed among CDR1 (28bAsn, 30bAsn), CDR2
(51bGly, 52bAla, 52bGly), and HV4 (72bGln). Residues
with significant yet more limited effects were also present
in each of these loops and in the FR3 region (57bLys).
Consistent with previous predictions that SAGs are largely
Vb specific, neither the bCDR3 loop nor the most promi-
nent residue (100aPhe) at the surface of the pMHC bind-
ing site contributed binding energy to the SEC3–TCR in-
teraction.
Although the most important residues shown in Fig. 5
are distributed throughout the linear sequence, the energy
map of these residues in the three dimensional structure re-
Figure 4. Competition ELISA of scTCR alanine mutants with SEC3-
1A4. Inhibition of SEC3-1A4 binding by representative 2C scTCR ala-
nine mutants. Wt and mutant scTCRs at various concentrations were
used to inhibit the binding of biotinylated SAG SEC3-1A4 to wt-scTCR
in an ELISA format. Bound biotinylated 1A4 was detected by streptavi-
din-HRP. The reactivity of each mutant was determined as the ratio of
mutant to wt IC50 by linear regression analysis.
Figure 5. Reactivities of scTCR alanine mutants with SEC3-1A4. Reactivities of mutant proteins were determined as IC50 values relative to wt by
linear regression analysis. Positive values (above the wt reference line of 0 reactivity) indicate a decrease in binding, and negative values indicate an in-
crease in binding. Error bars represent three or more independent experiments.840 Superantigen–TCR Interactions
nately, the contribution of 54bSer, which contacts SEC3
residues 23Asn and 91Val, could not be determined since
this alanine mutant failed to refold correctly.
In comparison to CDR2, the more limited influence of
HV4 residues on the SEC3 binding energy was consistent
with the observation that the HV4 loop possesses fewer
contacts in the 14.3.d b chain–SEC3 complex than the
CDR2 loop (16). Vb residues 70bPro and 71bSer, which
Figure 6. Sensorgrams of 2C TCR alanine mutants binding SEC3
variant 1A4. bK66A (A) and bY48A (B) were injected at the indicated
concentrations at a flow rate of 15 ml/min over a surface to which SEC3-
1A4 (500 RU) had been immobilized.
veals an energetic hotspot centered around CDR2 residues
51–53 (Fig. 7). This hotspot is surrounded by residues in
CDR1, HV4, and FR3 that contribute to the binding in-
teraction. With the exception of CDR1, each of these re-
gions has residues that are in contact with wt SEC3 in the
14.3.d Vb–SEC3 complex. Analysis of the interface of the
Vb–SEC3 complex (Fig. 8) suggests that the important res-
idues in CDR1 (28bAsn, 30bAsn) and HV4 residue
72bGln exert their effects by interacting with the region of
SEC3 that has been altered in the 1A4 variant (shown in
red on the small domain of SEC3). Accordingly, the bind-
ing energies measured for CDR1 residues 28bAsn and
30bAsn are likely contributing to the higher affinity associ-
ated with the Vb8–SEC3-1A4 interaction. The energy as-
sociated with these three residues (DDG z 4.8 Kcal/mol)
in the alanine scan could account for the 200–300-fold in-
crease in affinity of the SEC3-1A4 variant. We expect that
a structure of the mutant SEC3–TCR complex could help
substantiate this prediction, but for the purpose of examin-
ing the wt SEC3–Vb interaction, CDR1 residues 28bAsn
and 30bAsn and HV4 residue 72bGln will not be consid-
ered further.
The CDR2 region of the Vb domain of the TCR has
the majority of structural contacts in the complex with
SEC3 (15, 16). Residues 52bAla and 53bGly contact SEC3
residues 90Tyr and 210Gln, respectively, two residues that
were previously identified as TCR-binding “hotspots”
within SEC3 (Fig. 8; reference 17). The most significant re-
duction in binding was observed for residue 51bGly, which
also contacts SEC3 but does not contact SEB (16). Accord-
ingly, this position may in part account for the higher affin-
ity of Vb8.2 for SEC3 compared with SEB. Although the
two adjacent CDR2 residues 50bTyr and 56bGlu contact
SEC3 residues 91Val and 20Thr, respectively, mutation of
these residues did not show significant effects on binding.
Thus, like other protein–protein interactions, the energetic
hotspot of the SEC3–Vb8 interaction does not extend
across the entire interface. Vb residue 48Tyr, which is distal
to the Vb–SEC3 interface (Fig. 8), results in a moderate loss
of binding when changed to alanine, probably because of
effects this mutation has on the local conformation of the
CDR2 loop and possibly on FR3 residue 57bLys. Unfortu-
Table I. Binding Energetics of 2C scTCR Alanine-substituted 
Mutants
CDR
loop
TCR
residue
SEC3
structural
contacts*
Hydrogen
bond DDG‡
KD
BIAcore§
kcal/mol 6 SD nM
CDR1b T26 – – 20.07 6 0.10 –
N27 – – 0.14 6 0.03 –
N28 S–S loop – 1.36 6 0.18 –
N30 S–S loop – .2.12 6 0.34 .1,200
N31 – – 20.04 6 0.11 –
CDR2b Y48 – – 0.80 6 0.16 880
Y50 V91 – 20.10 6 0.20 160
G51 V91 – .2.12 6 0.20 .5,000
A52 Y90 – .2.12 6 0.39 .5,000
G53
N23, Y26,
Q210 Q210 .2.12 6 0.20 .5,000
S54 N23, V91 – – –
T55 T20, N23
T20,
N23(2) 1.13 6 0.20 –
E56 T20 – 0.14 6 0.24 –
FR3b K57 G19, T20 – 0.77 6 0.11 1,400
K66 F176 – 20.45 6 0.09 120
A67 F176 – – –
HV4b P70 L58 N60 0.30 6 0.15 –
S71 N60 – 0.43 6 0.27 –
Q72 S–S loop – 1.50 6 0.29 –
E73 – – 20.31 6 0.10 –
N74 – – 20.05 6 0.16 200
S76 – – 20.27 6 0.06 –
CDR3b G97 – – 0.18 6 0.15 400
T105 – – 20.09 6 0.15 –
L106 – – 0.07 6 0.23 –
Y107 – – 0.16 6 0.09 –
CDR3a F100 – – 0.04 6 0.14 220
*Contact residues and hydrogen bonding data are from the SEC3–
14.3.e  b chain complex (references 15, 16; Protein Data Bank [available
at http:\\www.rcsb.org/pdb] accession no. 1JCK.
‡Changes in free energy of binding were calculated from ELISA experi-
ments based on IC50 binding data relative to wt 2C scTCR. A maximum
value of 2.1 kcal/mol corresponds to a 50-fold decrease in binding.
§Dissociation constants were determined by BIAcore experiments. The
KD of wt 2C scTCR–SEC3-1A4 complex is 185 nM.841 Churchill et al.
are on the proximal side of the HV4 loop and in contact
with SEC3 residues 58Leu and 60Ser, contributed a moder-
ate amount of binding energy. Mutation of residues on the
distal side of the loop (73bGlu, 74bAsn, and 76bSer) did
not reduce SEC3 binding and in fact alanine mutants of res-
idues 73bGlu and 76bSer showed moderate increases in
binding (see below). Residue 74bAsn is a possible glycosyl-
ation site in the native TCR. The observation that mutation
of this position had no effect on SEC3 binding is consistent
with previous findings that glycosylation of the TCR does
not appear to affect SEC3 binding (43).
The two most accessible residues in Vb FR3, 57bLys and
66bLys, are both in contact with SEC3 in the crystal struc-
ture. Mutation of 57bLys led to a moderate reduction in
binding, probably due to the loss of multiple Van der Waals
(vdw) interactions with SEC3 residues 19Gly and 20Thr. In
contrast, alanine substitution of 66bLys led to a significant
enhancement of binding (see below).
There were no direct contacts between CDR3 of 14.3.d
TCR b chain and SEC3 observed in the crystal structure of
the complex (15). Consistent with this finding, mutations at
residues 97bGly, 105bThr, 106bLeu, and 107bTyr showed
minimal effects on SEC3 binding. A small but consistent re-
duction in binding of the Gly97Ala mutation was observed
in both the ELISA format (decrease of 1.4-fold) and by SPR
(KD 5 400 nM). This result may suggest that the CDR3
loop is in a position to effect in a moderate way the binding
of this SAG. As indicated above, Va residue 100aPhe is the
most prominent residue on the pMHC-binding surface
(35), yet it had no effect on binding SEC3. A recent study
has shown that Va CDR2 residues can affect binding to the
SEC3–MHC complex but not to SEC3 alone (18).
Enhanced Binding of TCR Mutants to SEC3. Most alanine
scanning studies reveal a fraction of mutations that lead to
slight increases in the binding of ligand (44). In the case of
the TCR–SEC3 interaction, mutations at three TCR resi-
dues (66bLys, 73bGlu, and 76bSer) showed minor but sig-
nificant increases in binding (Fig. 5). To determine if the
combination of these mutations would yield further in-
creases in affinity, all three residues were examined as dou-
ble and triple mutants (Fig. 9). Each of the three double
mutants exhibited affinities for the SEC3 that were above
the single-site mutants. The triple mutant yielded the high-
est affinity, approximately fivefold greater than the wt-
scTCR. The mechanism by which these modified side
chains act to increase the affinity is unknown, but presum-
ably the alanine mutations could: (a) eliminate steric inter-
ferences of the wt side chain, (b) stabilize the TCR in a
conformation that recognizes the ligand, or (c) allow in-
creased mobility of TCR regions that require such flexibil-
ity in the recognition of ligands. Our recent analyses of sev-
eral TCR mutants that bind pMHC with higher affinity
suggest that each of these possibilities might operate, de-
pending on the residue, its location in the structure, and
the ligand itself (45; and Lee, P.U.Y., H.R.O. Churchill,
and D.M. Krantz, unpublished findings).
Discussion
Alanine scanning mutagenesis has been used to charac-
terize the functional contribution of individual residues in
several protein–protein interactions, including antigen–
antibody interactions (27, 46) and TCR–SEC3 (17). Since
alanine substitution minimizes steric and/or electrostatic
constraints on the tertiary structure of a protein, this ap-
proach provides a systematic analysis of protein binding
Figure 7. Energy map of the 2C scTCR SEC3-
1A4 binding site. The face of the TCR Vb domain
that recognizes SEC3 is shown. The color scale indi-
cates the fold reduction in binding for each residue
upon alanine substitution (or tryptophan substitution
of 52bAla): red shows a .10-fold reduction in bind-
ing, purple shows a 1.5–9-fold reduction in binding,
yellow shows no effect on binding, and green shows
an increase in binding. 106bLeu (yellow) is not
shown. 54bSer was unable to be tested, as the alanine
mutant lacked Vb8-specific mAb activity. The 2C
TCR surface illustrated is from the 2C TCR crystal
structure (reference 35; Protein Data Bank [available
at http:\\www.rcsb.org/pdb] accession no. 1TCR).842 Superantigen–TCR Interactions
thermodynamics (26, 44). In this report, the relative contri-
butions of Vb residues in binding SEC3 were examined by
alanine scanning mutagenesis. From these results, the en-
ergy of the TCR interface with SEC3 can be mapped as
the change in binding free energy (DDG) for each mutation
(Table I, and Fig. 5). The CDR2, CDR1, HV4, FR3, and
CDR3 regions accounted for 59, 25, 11, 2, and 2%, re-
spectively, of the 2C TCR binding energy toward the
SEC3 variant 1A4. The mutated region of SEC3 in 1A4 is
within the disulfide loop. This loop is believed to be highly
flexible based on its poor resolution in crystal structures,
even at 1.5 Å resolution (47). Least square superpositioning
of structures of SEC3 and SEC3 in complex with the
14.3.d TCR b chain suggested that the loop could be very
close to residues within the Vb8 CDR1 and to HV4 resi-
due 72bGln. Thus, we suspect that these residues affected
binding to 1A4 because they are involved in contacts with
the mutated SEC3 region.
With this in mind, the thermodynamic results shown
here point to the significant energetic contribution of the
CDR2 loop in SEC3 recognition by Vb8.2 and they de-
fine this region as the hotspot of the TCR–SEC3 interac-
tion. This hotspot is located at the tip of CDR2, and it
involves predominantly residues 51bGly, 52bAla, and
53bGly. These are surrounded by a second shell of residues
that appear to contribute a moderate amount of energy to
the interaction: 55bThr, 57bLys, 70bPro, and 71bSer.
Residue 54bSer is located within the same region but it
Figure 8. Binding interface of the Vb8 domain and
SEC3. The binding interface of the TCR Vb8 (blue)
and SEC3 (green) is shown. Residues that were sub-
jected to alanine scanning in the TCR and SEC3 (ref-
erence 17) are shown. The color scale indicates the fold
reduction in binding for each residue: red shows the
greatest reduction in binding, purple shows a moderate
effect, yellow shows little effect, and green shows an
increase in binding. The SEC3 loop colored red indi-
cates the affinity maturation site of the SEC3-A4 vari-
ant. The region of CDR2b colored red (51bGly,
52bAla, 53bGly) contributed the greatest energy to the
interaction. A view of the CDR2b loop of the TCR
shows the topology of the c99 b strand in relation to the
c9 and d strands. Coordinates are derived from the
14.3.d TCR–SEC3 crystal structure (reference 15;
Brookhaven Protein Data Bank accession no. 1JCK).
Figure 9. Reactivities of double and triple scTCR alanine mutants
with SEC3-1A4. Fold increases of SEC3-1A4 reactivity were calculated
based on the relative IC50 of each mutant compared with wi using linear
regression analysis. Error bars represent the SD obtained from three sepa-
rate ELISA experiments.843 Churchill et al.
was unable to be tested because the alanine mutant did not
fold properly. The results are also consistent with the ala-
nine scan that was performed from the SEC3 side of the in-
teraction, in that most of the key residues in SEC3 are lo-
cated within proximity to the key residues in the Vb
domain (Fig. 8; reference 17). It is important to point out
that the exact energetic contributions of side chains within
the CDR2 loop cannot be determined from this analysis.
This is because analysis of the wt residues 51bGly, 52bAla,
and 53bGly necessitated mutation to larger groups at the
interface (51bAla, 52bTrp, and 53bAla, respectively), and
these modifications may act by interfering with main chain
interactions. Nevertheless, even more extensive changes
are seen among other Vb regions that are SEC3 reactive
(Table II; reference 3), suggesting that there are significant
compensatory interactions that occur at TCR–SEC3–
MHC interfaces (see below).
Direct comparison of the structures of the Vb8.2 domain
of the 14.3.d TCR and the corresponding domains of sev-
eral other TCRs suggested a possible explanation for the
Vb-related specificity of SEC3 and SEB (12, 16). The
14.3.d Vb8.2 region and the SEC3-reactive human
Vb12.3 from the A6 TCR (48) showed an root mean
squared (rms) difference of 0.9 Å when the 14 a-carbon at-
oms in the SEC3/SEB-binding site were superimposed. In
contrast, the 14.3.d Vb8.2 region and the SEC3-nonreac-
tive mouse Vb2.3 from the KB5-C20 TCR (49) showed
an r.m.s difference of 3.0 Å for the same 14 a-carbon at-
oms in the SEC3/SEB-binding site. This significant differ-
ence in alignment is due primarily to the c99 b strand hy-
drogen bonding to the outer b sheet d strand in Vb2.3,
instead of maintaining association with the c9 strand of its
inner b sheet, as is the case with Vb8.2 and Vb12.3 (16,
49). The altered orientation of the c99 strand in relation to
the c9 and d strands directly affects the conformations of
CDR2 and FR3 (Fig. 8). Therefore, the spatial integrity of
the c99 strand in relation to the c9 and d strands appears to
impose a conformational restriction that is important for
the binding motif of SEB and SEC3. This implies that
other Vb subsets that bind these SAGs may show c99 con-
formational similarity to mouse Vb8 and human Vb12.
Several of the mutations that affected SEC3 binding ap-
pear to act by disrupting this conserved topology within
the c99 and d strand interactions. For example, 48bTyr in-
teracts with 55bThr and 56bGlu on the c99 strand. The side
chain of 55bThr on the c99 strand is hydrogen-bonded to
its own main chain oxygen and involved in multiple vdw
interactions with 69bArg on the d strand. This mutation
could thereby disrupt hydrogen bonds that the c9 strand
shares with SEC3 residues 20Thr and 23Asn.
The results shown here also provide a rationale for the
importance of CDR2 residues 51–53 in the interactions of
Vb regions with SEC3 and SEB. Multiple hydrogen bonds
and vdw interactions are formed with these Vb8.2 residues
and the conserved SAG residues 23Asn, 60Asn, and 90Tyr
(16). However, the affinity of the Vb8.2 region for SEB
has been reported to be 100-fold less than for SEC3.
Glyb53 has 1 contact with SEB residue 23Asn but 11 addi-
tional vdw interactions with SEC3 residues 26Tyr and
210Gln. Since this position in CDR2 is a hotspot of SEC3
binding (DDG . 2 kcal/mol), loss of these multiple con-
tacts in the SEB complex may account for its lower affinity
for the TCR compared with SEC3. Consistent with this
possibility, mutation of SEB 26Val, which does not contact
53bGly, to the SEC3 residue tyrosine resulted in a higher
affinity for the SEB/26Tyr variant (KD z 12 mM; refer-
ence 17). Similarly, 51bGly has four contacts with SEC3
residue 91Val, but does not contact SEB residue 91Tyr.
Perhaps the most unexpected finding of the current
study is that there were significant effects of many single-
site mutations that are at the interface, but which lack di-
rect side chain interactions with the wt SEC3 in the struc-
ture. In this regard, 57bLys is the only residue that exhibits
side chain hydrogen bonds that contact SEC3. Other resi-
dues exhibit hydrogen bonds between main chain atoms
and SEC3. One might expect these interactions to be
largely sequence independent, consistent with the exten-
sive diversity present among SEC3-reactive Vb regions in
the residues at the interface. With this in mind, it is reason-
able to ask how do alanine substitutions reduce binding by
up to 100-fold (e.g., Gly51bAla and Gly53bAla), if the pri-
mary interactions involve hydrogen bonds between SEC3
and Vb main chain atoms? We consider two general fea-
tures of a Vb region that may be necessary (although not
sufficient) for productive binding to SEC3. First, as previ-
ously discussed, the overall topology of the Vb domain
Table II. Sequences of Mouse and Human Vb Regions That Are 
SEC3 Reactive
Vb family 50 51 52 53 54 55 56 57 66 70 71
mVb8.2 Y G A G S T E K K P S
Effect of mutation: *** *** *** ** ** ** **
mVb3Q N Q E V L Q Q S P S
mVb7Y D V D S N S E R K K
mVb1 0 N NKQLIV NSSS
mVb1 7 R NEEIM E QSSS
hVb3Y D V K M K E K S E K
hVb5F S E T Q R N K S F S
hVb12 Y G V K D T D K S S K
hVb13.2 V G E G T T A K N L K
hVb1 4 MNVEVTDKKKE
hVb15 F D V K D I N K S Q A
hVb17 Q I V N D F Q K S E K
hVb20 V G I G Q I S S S P Q
Amino acid residues that are present at positions near the Vb8–SEC3
interface are shown for various mouse (mVb) and human (hVb) TCRs
(reference 3). Effects of mutations on SEC3 binding by the Vb8.2
region are shown as ***.10-fold reduction in binding or as **1.5–9-fold
reduction in binding. All of the Vb8.2 residues shown were examined
in the present mutational analysis, except Serb54Ala, which was
defective in folding.844 Superantigen–TCR Interactions
must conform to that observed in the crystal structures of
the SEC3-reactive Vb domains (12). Second, even with
this scaffold, the conformations of CDR2 and HV4 loops
can be affected by single residues, thereby impacting spe-
cific main chain interactions with SEC3. These effects on
conformation might involve loop dynamics and mobility
without altering the major backbone conformation ob-
served in the crystal structures. A recent solution structure
of an scTCR observed such mobility, but primarily in the
CDR3 loops (50). Conformational plasticity was also ob-
served in the interaction of the 2C TCR with the pMHC
complex dEV8/Kb, but the major structural changes were
in CDR3a and, to a lesser extent, CDR1a (51). In addi-
tion, studies of single-site variants in antigen–antibody in-
teractions have shown that there can be entropic compen-
sation for losses of enthalpy (52).
If single-site mutations observed in this report can so
significantly affect SEC3 binding, then how do other
SEC3-reactive Vb regions, which have extensive diversity
in this same set of residues (Table II), maintain SEC3 reac-
tivity? Although the answer to this question will come
from detailed structural and mutagenic analyses of these
Vb regions, it is important to note that the binding affini-
ties of SEC3 for most of the different Vb regions have not
been measured (12). It is possible that the variability found
at key Vb positions will confer upon these Vb regions a
range of affinities for SEC3, some of which differ signifi-
cantly from that measured for the Vb8.2 region. Thus,
these interactions could exhibit a range of affinities that is
as large as the difference between the affinities measured
for Vb8.2 interacting with SEB and with SEC3 (z140-fold).
From the functional perspective, this is not an unreason-
able possibility, as it is clear that a 100-fold lower affinity of
the TCR–SAG interaction may only affect the biological
activity moderately, whereas the SAG–MHC affinity has a
greater effect on function (17, 53). As the Va region is
now thought to participate directly in the interaction with
class II MHC (at least in some cases), it is also possible that
some Vb–SEC3 interactions are below the measurable af-
finity range, yet the entire VaVb–SEC3–class II com-
plexes are sufficiently stable to elicit T cell activity. In this
model, the requirement for Va–class II interaction (and
perhaps CDR3 involvement) then depends on some basal
affinity of the Vb–SAG interaction. This possibility could
be tested by measuring the affinities of the different Vb re-
gions for SEC3 and examining the restrictions in Va use
(focusing on CDR2a in particular) among T cells bearing
the corresponding Vb region. The latter approaches have
already been taken for several SAGs, demonstrating that
some appear to require either CDR3 or Va interactions
(8, 19–25).
The observation that single amino acid differences in the
area of contact can reduce the binding energy by .10-fold
also provides an explanation for the diverse biological ef-
fects of the same SAG. Previous binding studies with
TCR–pMHC have shown that there is as little as a three-
fold difference in affinities between agonist and antagonist
responses (28, 29). It is apparent that minor differences in
Vb sequence, or residues in CDR3b or the Va region
could either reduce or enhance the basal affinity of the
Vb–SAG–MHC interactions. The range of outcomes
could be T cells that undergo full activation to T cells that
undergo anergy.
We have also shown here that it is possible to increase
the affinity of the TCR for SEC3 by approximately five-
fold through the selected combination of alanine muta-
tions. Although a fivefold increase is not likely to be suffi-
cient for using soluble versions of the TCR as SEC3
antagonists, it does provide a guide for further engineering
of high-affinity TCR by focusing on these residues. Fur-
thermore, the findings suggest that other Vb regions could
have evolved compensatory mutations that act by increas-
ing the affinities of the TCR for SAGs to some threshold
level. A study of the human growth hormone receptor
showed that analogous compensatory mutations at the hor-
mone interface acted through local structural rearrange-
ments in the region of contact (54). Some of these changes
affected residues at 15 Å distance from the mutation. Like-
wise, the interactions of mutants of D5.1 antilysozyme and
lysozyme have shown that altered residues can compen-
sate, even at long distances, through reorganization of sol-
vent at the interface (52, 55). It is reasonable to think that
the other Vb regions will likewise have local structural re-
arrangements at the SEC3 interface in order to achieve the
minimal affinity necessary (KD z100 mM) for stimulating
T cells. The fact that multiple solutions to this interaction
might have evolved among Vb regions with the same scaf-
fold suggests that there was strong selective pressure on
SAGs to maintain binding to these diverse T cells.
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